Abdulrahman K. Sinno¹, Aisha Mustapha¹, Navya Nair¹, Simona Zaami², Lina De Paola², Valentina Billone³, Eleonora Conti³, Giuseppe Gullo^3,*, Pasquale Patrizio⁴

Oncology Research, Vol.34, No.1, 2026, DOI:10.32604/or.2025.072176 - 30 December 2025

Abstract Cervical cancer related to human papillomavirus (HPV) is a leading cause of cancer-related mortality among women worldwide. Cancer cells release fragments of their DNA, known as circulating tumor DNA (ctDNA), which can be detected in bodily fluids. A PubMed search using the terms “ctHPV” or “circulating tumor DNA” and “cervical cancer”, limited to the past ten years, identified 104 articles, complemented by hand-searching for literature addressing medico-legal implications. Studies were evaluated for relevance and methodological quality. Detection and characterization of circulating tumor HPV DNA (ctHPV DNA) have emerged as promising tools for assessing prognosis and More >

Min Ma^1,2,3,#, Zhuxiu Wang^4,#, Yan Cao⁴, Juanying Yang⁴, Zeliang Zhuang⁵, Linqian Shi^4,*, Qian Gao^4,*

BIOCELL, Vol.49, No.12, pp. 2399-2413, 2025, DOI:10.32604/biocell.2025.071255 - 24 December 2025

Abstract Objectives: Keratin 6A (KRT6A) has been implicated in the progression of multiple malignancies; however, its expression pattern and biological role in cervical cancer (CC) have not been elucidated. This study aims to investigate KRT6A expression in CC tissues and evaluate its effects on cellular proliferation, migration, and invasion, thereby assessing its potential as a biomarker and therapeutic target. Methods: Differentially expressed genes were screened from the Gene Expression Omnibus (GEO) dataset (GSE9750) using the thresholds |log2FC| > 2 and false discovery rate (FDR) < 0.05. Immunohistochemistry was performed to evaluate KRT6A protein expression in tumor… More >

Oncology Research Editorial Offfce

Oncology Research, Vol.33, No.12, pp. 4157-4157, 2025, DOI:10.32604/or.2025.075991 - 27 November 2025

Abstract This article has no abstract. More >

YUANLIN LIU^1,3, YAN LIU², YAN WANG², QIANG WANG², YAN YAN¹, DANDAN ZHANG^2,*, HUIQIN LIU^2,*

Oncology Research, Vol.33, No.6, pp. 1505-1505, 2025, DOI:10.32604/or.2024.056768 - 29 May 2025

Abstract This article has no abstract. More >

GUANTING PANG^1,5,#, YAOHAN LI^2,5,#, QIWEN SHI³, JINGKUI TIAN⁵, HANMEI LOU^4,5,*, YUE FENG^4,5,*

Oncology Research, Vol.33, No.4, pp. 821-836, 2025, DOI:10.32604/or.2024.053772 - 19 March 2025

Abstract Immunotherapies have demonstrated notable clinical benefits in the treatment of cervical cancer (CC). However, the development of therapeutic resistance and diverse adverse effects in immunotherapy stem from complex interactions among biological processes and factors within the tumor immune microenvironment (TIME). Advanced omic technologies offer novel insights into a more expansive and thorough layer of the TIME. Furthermore, integrating multidimensional omics within the frameworks of systems biology and computational methodologies facilitates the generation of interpretable data outputs to characterize the clinical and biological trajectories of tumor behavior. In this review, we present advanced omics technologies that More >

Lingling Zhang^1,2, Hualing Wang³, Yawen Liu², Ling Li^2,*, Jianping Xiong^1,4,*

BIOCELL, Vol.49, No.2, pp. 253-267, 2025, DOI:10.32604/biocell.2025.061585 - 28 February 2025

Abstract Objective: Anillin (ANLN) is considered an oncogene in various cancers, but its effect on cervical cancer remains poorly understood. Hence, this study aimed to describe the action of ANLN on cervical cancer development and investigate the potential mechanism. Methods: Analysis of ANLN expression and its association with survival in carcinoma and endocervical adenocarcinoma (CESC) patients based on GEO and UALCAN databases. The tumor and adjacent normal tissues of 100 cervical cancer cases were harvested to detect the ANLN expression and explore its relationship with patient survival. Cell proliferation, apoptosis, migration, and invasion were measured by… More >

CHAOQUN WANG¹, TING ZHANG², CHAOHE ZHANG^3,*

Oncology Research, Vol.32, No.12, pp. 1867-1879, 2024, DOI:10.32604/or.2024.044547 - 13 November 2024

Abstract Background: Drug resistance is the main factor contributing to cancer recurrence and poor prognosis. Exploration of drug resistance-related mechanisms and effective therapeutic targets are the aim of molecular targeted therapy. In our study, the role of long non-coding RNA (lncRNA) AFAP1-AS1 in gemcitabine resistance and related mechanisms were explored in cervical cancer cells. Methods: Gemcitabine-resistant cervical cancer cell lines HT-3-Gem and SW756-Gem were constructed using the gemcitabine concentration gradient method. The overall survival rates and recurrence-free survival rates were evaluated by Kaplan-Meier analysis. The interaction was verified through a Dual-luciferase reporter gene assay and a… More > Graphic Abstract

Oncology Research Editorial Office

Oncology Research, Vol.32, No.11, pp. 1817-1817, 2024, DOI:10.32604/or.2024.056892 - 16 October 2024

Abstract This article has no abstract. More >

Oncology Research Editorial Office

Oncology Research, Vol.32, No.9, pp. 1539-1539, 2024, DOI:10.32604/or.2024.056126 - 23 August 2024

Abstract This article has no abstract. More >

Oncology Research Editorial Office

Oncology Research, Vol.32, No.8, pp. 1371-1371, 2024, DOI:10.32604/or.2024.055030 - 17 July 2024

Abstract This article has no abstract. More >